As the Inflation Reduction Act empowers Medicare to negotiate drug prices based in part on clinical benefit, and as the FDA more closely scrutinizes accelerated approvals, a fundamental question has become increasingly important: what exactly constitutes “innovation” in biopharma? To date, our answers have largely focused on counting—company R&D investment, drug approvals, and patents. But

The Incidental Economist

12.09.2025

Libraries are health hubs: why eliminate them? | The Incidental Economist

Cutting federal funding for the 9,000 public libraries serving as vital, local health hubs would negatively impact communities.

home›The Incidental Economist

The Incidental Economist

Economy

A Primer on Pharmacy Benefit Managers | The Incidental Economist

Older Americans Backing Trump Now Face Cuts to Medicaid, Services | The Incidental Economist

Measuring Biopharmaceutical Innovation in the Modern Era | The Incidental Economist

Libraries are health hubs: why eliminate them? | The Incidental Economist

home
›
The Incidental Economist